AIQ Solutions develops the TRAQinform IQ software medical device, which quantifies changes in cancer lesions over time using serial radiographic images. This technology enables oncologists to tailor treatment regimens for late-stage cancer patients, addressing the challenge of treatment response heterogeneity that can significantly impact clinical outcomes.
Funding
$16M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
SBFounders
Product
Problem
Late-stage cancer treatment is often hindered by the heterogeneous response of individual lesions to therapy, leading to suboptimal clinical outcomes. Current standard-of-care methods may not accurately capture these variations in treatment response across all lesions within a patient. This limitation makes it challenging for oncologists to tailor treatment regimens effectively.
Solution
AIQ Solutions offers TRAQinform IQ, a software medical device that quantifies changes in cancer lesions over time using serial radiographic images, such as PET and CT scans. The software analyzes uploaded images to provide quantitative and spatial information about each region of interest. By evaluating treatment response heterogeneity, TRAQinform IQ enables clinicians to more precisely adjust therapies and optimize clinical outcomes for late-stage cancer patients. The technology integrates into existing clinical workflows, delivering a comprehensive report to the oncologist with actionable insights.
Target Audience
The primary users are oncologists and clinicians treating late-stage cancer patients who require precise monitoring of treatment response and individualized therapy adjustments.
Features
- Analyzes serial radiographic images (PET, CT) to quantify lesion changes over time.
- Provides spatial and quantitative data on each region of interest.
- Calculates SUVhetero, an imaging metric of intra-patient heterogeneity.
- Generates comprehensive reports delivered to oncologists for treatment planning.
- Cloud-based image upload ensuring HIPAA compliance.
- FDA cleared for clinical use under 510(k) K233998.